-40%

BLOOMBERG LAW PATENTS AND THE FEDERAL CIRCUIT 2016

$ 23.76

Availability: 100 in stock
  • All returns accepted: Returns Accepted
  • Publication Year: 2016
  • Publication Name: BNA
  • Type: Law Book
  • Author: Harmon Homan
  • Return shipping will be paid by: Buyer
  • Item must be returned within: 30 Days
  • Subject: Law
  • Condition: Very Good
  • Refund will be given as: Money Back
  • Restocking Fee: No

    Description

    This landmark reference deals with both the high-profile cases and the “uncelebrated decisions” that tend to slip under the radar and fits them into an analytical framework that reveals their true significance.
    Patents and the Federal Circuit
    addresses ever-changing issues and developments in substantive patent law, infringement litigation, and procedure. The authors distill the opinions issued by the primary source of governing law on patents, providing convenient, one-source access to controlling case law.
    The
    Fourteenth Edition
    includes a new appendix with guidance on the time to decision for the Federal Circuit’s patent decisions, including statistics on the time from argument to issuance of a precedential decision by judge.
    Discussion of new Supreme Court and key Federal Circuit decisions include:
    Supreme Court decisions through June 2019, including
    Helsinn Healthcare SA v. Teva Pharmaceuticals USA Inc
    ., 139 S. Ct. 628 (2019), and
    Return Mail, Inc. v. U.S. Postal Serv.
    , 139 S. Ct. 1853, 1867 (2019).
    Decisions concerning the Federal Circuit’s evolving precedent on patent eligibility under 35 U.S.C. 101, including,
    inter alia
    ,
    Roche Molecular Sys., Inc. v. Cepheid
    , 905 F.3d 1363, 1372 (Fed. Cir. 2018);
    SAP Am., Inc. v. InvestPic, LLC
    , 898 F.3d 1161, 1162 (Fed. Cir. 2018);
    Voter Verified, Inc. v. Election Sys. & Software, LLC
    , 887 F.3d 1376 (Fed. Cir. 2018);
    Aatrix Software, Inc. v. Green Shades Software, Inc
    ., 882 F.3d 1121, 1125 (Fed. Cir. 2018);
    Berkheimer v. HP, Inc
    ., 881 F.3d 1360 (Fed. Cir. 2018);
    Praxair Distrib. v. Mallinckrodt Hosp. Prods. IP
    , 890 F.3d 1024, 1032 (Fed. Cir. 2018);
    In re Marco Guldenaar Holding B.V.
    , 911 F.3d 1157 (Fed. Cir. 2018);
    In re Nordt Dev. Co., LLC
    , 881 F.3d 1371, 1374-75 (Fed. Cir. 2018); and
    Vanda Pharms. Inc. v. West-Ward Pharms. Int’l Ltd
    ., 887 F.3d 1117, 1121 (Fed. Cir. 2018).
    Revisions to address U.S. Patent Trial and Appeal Board procedure for post-grant proceedings under the America Invents Act in light of the rapidly-evolving law in this area